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929(Cx43) is the primary gap junction protein responsible for con-
duction in the ventricles. Slow conduction and consequent
increased arrhythmic risk afterMI are, in part, the result of Cx43
down-regulation, resulting in decreased conduction velocity
(CV) and creating the substrate for arrhythmia (7,8).
Recently, activation of the proto-oncogene tyrosine-
protein kinase cellular-Src (c-Src) has been linked to the
dysregulation of Cx43 in the heart (9–11). Cx43 is known to
interact with the scaffolding protein zonula-occludens-1
(ZO-1), which is a crucial regulator of gap junction size,
stabilization, and function (12–17). ZO-1 has complicated
effects on gap junctions. Overexpression can inhibit Cx43
incorporation into gap junctions (14), but displacement of
ZO-1 from gap junctions leads to their internalization (18).
Phosphorylation of c-Src on Tyr416 (phosphorylated, active
c-Src [p-Src]) creates an active form of the kinase that can
displace the ZO-1/Cx43 interaction (12,13,16,18,19). p-Src
membrane localization results in internalization and degra-
dation of cardiac Cx43 (9–11).
c-Src is a nonreceptor tyrosine kinase of the Src family of
kinases that has been implicated in cell growth, differenti-
ation, cell adhesion, and tumorigenesis (20). Inhibitors of
c-Src activation, such as 4-amino-5-(4-methylphenyl)-7-(t-
butyl)pyrazolo[3,4-d]-pyrimidine (PP1), have been developed
that have proven beneﬁcial in slowing tumorigenesis (21–25).
Newer c-Src inhibitors, including N-(5-chlorobenzo[d][1,3]
dioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetra-
hydro-2H-pyran-4-yloxy)quinazolin-4-amine (AZD0530,
also known as Saracatinib [AstraZeneca, London, United
Kingdom]), are in clinical development and have proven
tolerable in human cancer studies (26,27). Recently, we
studied mice with a cardiac-speciﬁc activated renin-
angiotensin system and showed that PP1 inhibition of c-Src
activation restores Cx43 expression and conduction velocity
and decreases arrhythmias and sudden cardiac death (11),
suggesting usefulness of c-Src inhibition in preventing
arrhythmias associated with heart failure. Because c-Src has
been shown to be activated in animal models of MI (10), we
tested the hypothesis that c-Src inhibition could ameliorate
Cx43 degradation, increase conduction velocity, and decrease
arrhythmic risk after MI.
Methods
Detailed methods are available in the Online Appendix.
Brieﬂy, 12-week-old male C57BL/6 mice underwent either
sham surgery or coronary artery ligation to induce MI. Two
weeks after surgery, heart function was evaluated using
echocardiography as previously described (28). Animals with
MI who met inclusion criteria (ejection fraction <45%) were
randomized into treatment groups including the c-Src in-
hibitor PP1 (n ¼ 49), the inactive analogue, 4-amino-
7-phenylpyrazol[3,4-d]-pyrimidine (PP3) (n ¼ 42), saline
(n ¼ 12), or the c-Src inhibitor AZD0530 (Saracatinib,
AstraZeneca) (n¼ 12). Animals were treated for 2 weeks and
compared to shammice (n¼ 24). After 2 weeks of treatment,cardiac function was evaluated
again using echocardiography.
Then, animals underwent optical
mapping or inducibility studies
and were euthanized for tissue
collection. Optical mapping was
performed on 17 mice (7 PP1,
6 PP3, and 4 sham), and con-
duction velocity was calculated
as previously described (29). Ar-
rhythmia inducibility was evalu-
ated using epicardial burst pacing
protocols on sham (n ¼ 6), PP1
(n¼ 17), and PP3 (n¼ 17) mice.
Harvested tissue was evaluated by
immunoblotting, immunohisto-
chemistry, and quantitative poly-
merase chain reaction as previously
described (11). Telemetry electro-
cardiographic analysis was per-
formed for 4 weeks following
surgery on sham (n ¼ 4), PP1
(n ¼ 4), and PP3 (n ¼ 4) mice.
Data are expressed as mean 
SE. Statistical tests were con-
sidered signiﬁcant at p< 0.05. The animal experiments were
handled according to the National Institutes of Health Guide
for Care and Use of Experimental Animals, and use was
approved by the University of Illinois Institutional Animal
Care and Use Committee.Results
Left ventricular function after MI was unaffected by
c-Src inhibition. Following coronary artery ligation, mice
in both the PP1 and PP3 treatment groups developed large
anterior infarcts, increased reactive oxygen species (ROS)
production, and decreased left ventricular function. There
were no differences in MI size by area (PP3: 35  3%,
PP1: 34  4%, p ¼ 0.82) between treatment groups. ROS
production, as measured by nitrotyrosine staining, was
elevated comparably in both the PP3- and PP1-treated MI
groups as compared to sham (PP3 scar border: 172  7%
[p < 0.0001], PP3 distal ventricle: 164  10% [p < 0.0001],
PP1 scar border: 163  8% [p < 0.0001], PP1 distal
ventricle: 153  7% [p ¼ 0.001]). Echocardiography data,
taken before and after treatment, demonstrated decreased
ejection fraction in both the PP3- and PP1-treated groups
compared to shams. PP3- and PP1-treated mice had
increased end-systolic and -diastolic volumes as well as
decreased fractional shortening compared to shams (Fig. 1,
Table 1). Treatment with PP1 did not affect ejection
fraction, fractional shortening, or volume measurements
compared with the inactive PP3. The lack of difference
between treatment groups in infarct size and left ventricular
Figure 1 Wall Motion Defects and Evidence of ROS Production After MI
(A) Representative echocardiography images of sham and myocardial infarction (MI) mice, demonstrating scar formation and decreased anterior wall movement in the MI model.
(B) Representative images of ﬂuorescent nitrotyrosine stains indicative of increased reactive oxygen species (ROS) in the distal ventricle and scar border of PP3- and PP1-
treated post-MI mice. Quantiﬁcation of RFUs demonstrates signiﬁcantly elevated ROS in the distal ventricle and scar border of both PP3 and PP1 groups compared with sham.
There were no differences between treatment groups. RFU ¼ relative ﬂuorescent unit.
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930function implied that any arrhythmic changes were not likely
related to an inﬂuence on cell necrosis or left ventricular
function.Table 1 Echocardiography, Electrophysiology, and Scar Size
Sham PP3 PP1
2 weeks following MI
Ejection fraction, % 59  1 38  1* 38  1*
End-systolic volume, ml 34  2 84  5* 78  4*
End-diastolic volume, ml 79  4 133  6* 125  5*
Stroke volume, ml 45  3 49  2 48  2
Fractional shortening, % 29  1 18  1* 19  1*
Heart rate, beats/min 561  24 579  32 609  40
RR interval, ms 109  2 106  4 100  2
QRS duration, ms 8  1 10  1* 10  1
QT interval, ms 20  2 27  2 25  1
4 weeks following MI
Ejection fraction, % 60  2 38  2* 38  1*
End-systolic volume, ml 37  4 90  7* 87  7*
End-diastolic volume, ml 91  6 141  8* 137  9*
Stroke volume, ml 53  2 52  3 50  3
Fractional shortening, % 32  2 19  1* 18  1*
Heart rate, beats/min 569  30 587  20 556  26
RR interval, ms 100  2 105  4 100  2
QRS duration, ms 9  1 11  1* 11  1*
QT interval, ms 26  2 29  2 25  2
Infarct size, % 35  3 34  4
Values are mean  SE. *p < 0.05 versus sham. Infarct size was calculated as percentage of total
circumferential length occupied by scar by averaging 3 cross sections through the left ventricle.
There were no signiﬁcant changes between PP1 and PP3 groups.
MI ¼ myocardial infarction; RR ¼ electrocardiographic R wave to R wave interval.c-Src was activated following MI and inhibited by PP1
treatment. PP1 treatment prevented c-Src activation in
both regions of the heart following MI. At the scar border of
PP3-treated MI mice, p-Src expression was elevated to 280
 42% of sham levels (p ¼ 0.003). The scar border of PP1-
treated mice showed no signiﬁcant change in p-Src compared
with sham (86  16%, p ¼ 0.95). In the distal ventricle of
PP3-treated mice, p-Src expression was increased by 346
 75% of that of sham mice (p ¼ 0.013). The distal ventricle
of PP1-treated mice had no signiﬁcant change in p-Src
compared with sham (94  57%, p ¼ 1.0). PP1 treatment
maintained p-Src at basal expression levels in both the scar
border and distal ventricle (Fig. 2).
c-Src inhibition lessened Cx43 down-regulation
following MI. Because gap junction proteins are reduced
after MI and are major determinants of CV, we measured
Cx43 changes after MI with and without c-Src inhibition
(Fig. 2). In the scar border of PP3-treated mice, Cx43
expression was reduced to 22  3% of sham levels
(p < 0.0001). PP1 improved scar border Cx43 levels to
37  4% of sham expression (p ¼ 0.0001). This change
represents a 69% increase in Cx43 expression attributable to
c-Src inhibition (p¼ 0.048). In the distal ventricle, PP3 mice
expressed 29  6% of the Cx43 of sham mice (p < 0.0001),
whereas PP1 mice expressed 50  4% of sham Cx43
(p< 0.0001). PP1 mice had a 73% increase in distal ventricle
Cx43 compared to PP3 (p ¼ 0.043). Cx43 messenger ribo-
nucleic acid levels were not statistically signiﬁcantly changed
between treatment groups in the distal ventricle, but there
Figure 2 c-Src Inhibition With PP1 Improves Cx43 Levels After Myocardial Infarction
(A) Representative images of phosphorylated, active tyrosine kinase cellular-Src (p-Src), connexin43 (Cx43), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) Western
blots. Cx43 blots are subcategorized into P0, P1, or P2 bands reﬂecting increasing levels of phosphorylation. (B) Quantiﬁcation of band intensity of p-Src and Cx43 normalized
to GAPDH expression and relative to sham expression levels. (C) Distribution of Cx43 phosphorylation states according to treatment group. *p < 0.05; **p < 0.01; ***p <
0.001. c-Src ¼ tyrosine kinase cellular-Src; MI ¼ myocardial infarction.
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931was a trend toward increased Cx43 messenger ribonucleic
acid in the PP1-treated tissue (p ¼ 0.08) (Online Fig. 1).
Immunohistochemical staining showed no evidence of im-
provement in Cx43 lateralization with c-Src inhibition (data
not shown), suggesting that redistribution of Cx43 was not a
major cause of the Cx43 changes observed.
c-Src inhibition appeared to enhance Cx43 phosphorylation
following MI. Ischemia is associated with dephosphoryla-
tion of Cx43 (30). Generally, higher degrees of phosphor-
ylation are associated with increased Cx43 function and with
reduced electrophoretic mobility (31). Cx43 mobility was
evaluated in MI groups treated with PP3 and PP1 by cat-
egorizing bands as P0, P1, or P2 based on band migration
as has been previously described (Fig. 2) (32). At the scar
border, PP1-treated mice had signiﬁcantly higher P2
(p¼ 0.03) and P1 (p¼ 0.01) band concentrations than PP3-
treated mice, with no change in P0 expression (p ¼ 0.54).
In the distal ventricle, the P2 band was elevated (p ¼ 0.008)
compared with PP3, with no signiﬁcant changes in P1
(p ¼ 0.22) or P0 (p ¼ 0.12). This suggests that PP1 treat-
ment enhanced Cx43 phosphorylation in both regions of the
MI heart.
c-Src inhibition enhanced conduction velocity and
reduced arrhythmic inducibility following MI. Regional
CV was measured in sham, PP1, and PP3 groups via op-
tical mapping. At a 160 ms pacing cycle, CV was 47  2
cm/s in sham ventricle. CV was reduced to 32  2 cm/s in
the scar border of PP3-treated mice (p < 0.01 comparedwith sham) and reduced only to 41  2 cm/s in PP1-
treated mice (p < 0.05 compared with sham). This rep-
resents a signiﬁcant restoration of CV by PP1 treatment
compared with PP3 (p < 0.05). Comparable restoration of
CV by PP1 was seen in the distal ventricle at various cycle
lengths (Fig. 3). The CV changes are consistent with the
changes predicted by cable theory for the increase in Cx43
observed (33). Additionally, there were no signiﬁcant
changes in action potential duration between groups (data
not shown), and the changes in CV could not be explained
by changes in sodium channels, the other major determi-
nant of CV. Sodium channel expression was evaluated in
sham and distal ventricle of PP3 and PP1-treated mice,
and there were no signiﬁcant changes between any groups
(Online Fig. 1).
c-Src inhibition reduced ventricular arrhythmic induc-
ibility (Fig. 4). Ventricular epicardial burst pacing protocols
demonstrated no inducibility in the sham group (0 of 6
mice) and 71% inducibility in placebo-treated mice (12 of 17
mice). c-Src inhibition with PP1 reduced inducibility of MI
mice to 35% (6 of 17 mice; p ¼ 0.04 compared with PP3).
AZD0530 prevents p-Src activation and Cx43 degradation
following MI. Although PP1 is not used in humans,
AZD0530, a clinically relevant p-Src inhibitor, has proven
safe in patients (27). Daily gavage administration of
AZD0530 showed prevention of p-Src activation and pro-
tection of Cx43 expression compared with a saline-treated
control group (Online Fig. 2). p-Src expression was
Figure 3 c-Src Inhibition Improves Conduction Velocity After MI
(A) Representative images of activation maps of sham, PP1-, and PP3-treated mice. (B) Conduction velocities of PP1, PP3, and sham mice at the distal ventricle and scar
border. Sham mice could not be consistently captured at cycle lengths faster than 140 ms. *p < 0.05; **p < 0.01. Abbreviations as in Figure 2.
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932elevated in saline-treated mice compared to sham levels at
the scar border (335  77%, p ¼ 0.024) and distal ventricle
(422  92%, p ¼ 0.01) but was normalized in AZD0530-
treated mice (scar border: 135  73%, p ¼ 0.88, distal
ventricle: 167  91%, p ¼ 0.74).Figure 4 c-Src Inhibition Reduces Arrhythmia Inducibility After MI
(A) Representative electrocardiography at the initiation of stimulus protocol. (B) Represen
each treatment arm that were or were not inducible. *p < 0.05. NSVT ¼ nonsustained ven
monomorphic ventricular tachycardia; Stim ¼ stimulus artifact; other abbreviations as inIn the scar border of saline-treated mice, Cx43 expres-
sion was reduced to 14  1% of sham levels (p < 0.0001).
AZD0530-treated mice had Cx43 levels at 59  11% of
sham expression (p ¼ 0.021). This change represents a
321% increase in Cx43 expression attributable to c-Srctative electrocardiography patterns with stimulus pacing. (C) The number of mice in
tricular tachycardia; PMVT ¼ polymorphic ventricular tachycardia; SMVT ¼ sustained,
Figure 2.
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933inhibition (p ¼ 0.012). In the distal ventricle, saline-treated
mice expressed 31  5% of the Cx43 of sham mice
(p ¼ 0.0002), whereas AZD0530-treated mice expressed
51  4% of sham Cx43 (p ¼ 0.004). We did not ﬁnd a
signiﬁcant change between saline and AZD0530-treated
mice in Cx43 expression (p ¼ 0.25).
Discussion
Both MI and ischemic cardiomyopathy are associated with
increased risk of sudden death (2). This increase in malig-
nant arrhythmias is thought to be secondary to reduced
conduction velocity with its attendant increase in risk of
re-entry (4,8). Conduction slowing has been shown to be
worse at the scar border and at least in part a result of Cx43
down-regulation (8). Restoration of myocardial Cx43 by
gene-therapy and cell engraftment have both been shown to
lower VT inducibility following MI (34,35). In this work,
we show that c-Src inhibition lessened the reduction in
Cx43, improved conduction velocity, and reduced
arrhythmia inducibility following MI. The effect of c-Src
inhibition was independent of changes in ROS production,
ﬁbrosis, ejection fraction, electrocardiographic parameters,
action potential duration, or sodium channel expression.
The effects of c-Src inhibition in MI were consistent with
those seen with renin-angiotensin system activation, sug-
gesting that inhibition of a signaling pathway activated by
angiotensin II may explain the effect of c-Src inhibitors (11).
Renin-angiotensin system activation has been associated
with increased ROS, and increased ROS production has
been linked to c-Src phosphorylation in other models
(36,37). Because c-Src inhibition affected Cx43 without
affecting ROS, our data are consistent with a model where
increased ROS after MI activates c-Src resulting in Cx43
degradation and decreased CV.
p-Src levels were signiﬁcantly elevated, and Cx43 levels
were reduced in both the scar border and distal ventricle of
the post-MI heart. Inhibition of p-Src using the c-Src in-
hibitors PP1 and AZD0530 resulted in a return to near basal
p-Src levels and increased Cx43 expression (Fig. 2, Online
Fig. 2). Previous work in Cx43 knockout and heterozy-
gous mice has shown that one-half of the normal Cx43
expression is sufﬁcient to support normal current propaga-
tion (38). In our model, c-Src inhibition restored the gap
junction protein to 50% in the distal ventricle of the post-MI
heart and signiﬁcantly raised expression at the scar border.
Therefore, the improvement in CV and the decrease in
arrhythmic inducibility with c-Src inhibition were consistent
with the changes in Cx43 levels observed. Although Cx43
restoration was sufﬁcient to explain the beneﬁcial effects
after c-Src inhibition, the data suggest that there is an un-
discovered second process preventing full restoration of
Cx43 levels. Moreover, the data suggest that the processes
causing Cx43 degradation are evenly activated in the left
ventricular myocardium, rather than being localized to the
peri-infarct region.We observed an increase in slowly migrating forms of
Cx43 with c-Src inhibition. These forms are commonly
considered to represent increasingly phosphorylated Cx43
that have been associated with increased gap junction
function (39,40). Speciﬁc phosphorylation sites on the
channel have various activities (40), and in this work, we did
not evaluate changes in speciﬁc Cx43 phosphorylation sites.
Nevertheless, our data are consistent with previous ﬁndings
that increased Cx43 forms with decreased electrophoretic
mobility are associated with enhance gap junctional activity.
The mechanism linking p-Src inhibition to these Cx43
forms remains unclear.
Whereas PP1 is not a clinically relevant drug, AZD0530
has already been proven safe in phase 1 and 2 clinical trials
(24–27). The efﬁcacy of AZD0530 was similar to that of
PP1 and suggests that translation of these ﬁndings to trials
in man may be achievable.
Study limitations. This study focused on Cx43 regulation 2
to 4 weeks following MI. Although we found salutary effects
of c-Src inhibition when starting the drug 2 weeks after MI,
it remains to be seen if starting c-Src inhibition immediately
after MI would be advantageous. In a myocardial cryoinjury
model, treatment with a peptide mimetic of the Cx43 carboxy
terminus immediately following injury resulted in increased
Cx43 phosphorylation and a lower incidence of inducible
arrhythmia (41). Conversely, limiting gap junction commu-
nication by using carbenoxolone or Cx43 heterozygous mice
has shown a beneﬁcial effect by limiting scar size following
ischemia (42,43), suggesting an initial beneﬁt of Cx43 down-
regulation. A mouse with modiﬁed Cx43 preventing in-
activation has shown increased infarct size (44). Long-term
effects of c-Src inhibition have not been evaluated fully in
humans. Finally, recent work has raised concerns about QT
prolongation in animals treated with tyrosine kinase inhibitors
(45). We did not observe QT prolongation via telemetry
analysis or signiﬁcant increases in action potential duration,
but further study of repolarization may be warranted.
Conclusions
Inhibition of c-Src following MI increases Cx43, improves
CV, reduces arrhythmia inducibility, and may represent
a new approach to arrhythmia reduction in ischemic
cardiomyopathy.
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